Provided by Tiger Trade Technology Pte. Ltd.

VanEck Pharmaceutical ETF

114.51
+1.431.26%
Pre-market: 114.510.00000.00%04:00 EDT
Volume:290.40K
Turnover:33.26M
Market Cap:1.03B
PE:92.78
High:115.80
Open:115.15
Low:114.21
Close:113.08
52wk High:118.00
52wk Low:85.91
Shares:8.99M
Float Shares:8.99M
Volume Ratio:0.93
T/O Rate:3.23%
Dividend:2.17
Dividend Rate:1.90%
EPS(TTM):1.23
EPS(LYR):0.7765
ROE:--
ROA:--
PB:--
PE(LYR):147.47

Loading ...

States Namenda Tablets not Withdrawn for Safety or Effectiveness Reasons - Federal Register

THOMSON REUTERS
·
Aug 31

FDA: Will not Begin Procedures to Withdraw Approval of Abbreviated New Drug Applications That Refer to Namenda Products - Federal Register

THOMSON REUTERS
·
Aug 31

Lilly is Bigger than Ever. Why Its Latest $2.9 Billion Immunology Deal Makes Sense.

Dow Jones
·
Aug 31

AbbVie to Present at Wells Fargo Healthcare Conference

Reuters
·
Aug 31

Eli Lilly's Psoriasis Drug Trial Shows Sustained Positive Results

Dow Jones
·
Aug 31

Lilly to Buy This Autoimmune Drugmaker for $2.9 Billion in Cash. What it Means for the Stock.

Dow Jones
·
Aug 31

Eli Lilly announces 52-week results from TOGETHER-PsO, TOGETHER-PsA

TIPRANKS
·
Aug 31

Eli Lilly - Taltz and Zepbound Lead to Deeper Improvements in Systemic Inflammation in Both Trials

THOMSON REUTERS
·
Aug 31

New Phase 3B Data on Lilly's Taltz (Ixekizumab) and Zepbound (Tirzepatide) Used Together Showed Improved and Durable Efficacy at One Year in Adults with Psoriatic Disease and Obesity

THOMSON REUTERS
·
Aug 31

Eli Lilly - Taltz and Zepbound Maintain or Improve Disease Activity at Week 52 Versus Taltz Alone

THOMSON REUTERS
·
Aug 31

Eli Lilly: Adverse Events in Participants Treated with Taltz and Zepbound Together were Generally Mild to Moderate

THOMSON REUTERS
·
Aug 31

Lilly to Acquire Merida Biosciences in Deal Worth up to USD 2.88 Billion

Reuters
·
Aug 31

Eli Lilly: Under Terms of Agreement, Lilly Will Acquire Merida and Pay up to $2.875 Bln in Cash

THOMSON REUTERS
·
Aug 31

Lilly to Acquire Merida Biosciences to Advance Treatments for Serious Autoimmune and Allergic Diseases

THOMSON REUTERS
·
Aug 31

Eli Lilly - Deal Expected to Close in Q4 2026 Subject to Regulatory Approvals

THOMSON REUTERS
·
Aug 31

Pharma Industry Stares Down Biggest Patent Cliff in Decades

Dow Jones
·
Aug 29

AbbVie Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Aug 29

Eli Lilly (LLY) Wins FDA Approval For Mounjaro Heart Risk Reduction

Simply Wall St.
·
Aug 29

AbbVie Targets Rare Blood Disorder With New Phase 3 Etentamig Trial Plan

TIPRANKS
·
Aug 29

Novo Nordisk A/S Series B Stock Rises Friday

Dow Jones
·
Aug 29